Kristina Ray, MD
Internal Medicine · Wilmer, ALNPI 1598831422
Payments from drug & device makers
Across 190 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bayer$283
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$227
- AstraZeneca$224
- Organogenesis Inc.$205
- Novo Nordisk$192
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,57899%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 66 | $1,238 |
| Bayer | 15 | $283 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $227 |
| AstraZeneca | 13 | $224 |
| Organogenesis Inc. | 4 | $205 |
| Novo Nordisk | 10 | $192 |
| Lilly USA, LLC | 12 | $191 |
| Johnson & Johnson | 10 | $157 |
| Pfizer | 8 | $139 |
| Otsuka America Pharmaceutical, Inc. | 4 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| Axsome Therapeutics, Inc. | 3 | $77 |
| GSK | 4 | $61 |
| Novartis | 4 | $59 |
| Boehringer Ingelheim | 2 | $56 |
| Eisai Inc. | 3 | $52 |
| Amarin Pharma, Inc. | 3 | $47 |
| Exact Sciences | 2 | $44 |
| Amgen | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Merck | 2 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Genentech USA, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,599 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 173 | $206,892 |
| OzempicSemaglutide | 148 | $173,426 |
| EliquisApixaban | 198 | $137,739 |
| FarxigaDapagliflozin Propanediol | 148 | $137,074 |
| JardianceEmpagliflozin | 100 | $94,555 |
| TrulicityDulaglutide | 89 | $87,830 |
| RybelsusSemaglutide | 49 | $75,042 |
| Tresiba Flextouch U-200Insulin Degludec | 57 | $49,835 |
| JanuviaSitagliptin Phosphate | 54 | $45,744 |
| XareltoRivaroxaban | 56 | $30,567 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $30,086 |
| VraylarCariprazine Hcl | 16 | $30,034 |
| LinzessLinaclotide | 41 | $29,224 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 23 | $27,760 |
| ProliaDenosumab | 16 | $27,713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $191 | $294,722262 claims |
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6 | $192 | $276,229220 claims |
| PfizerEliquis, Premarin | $139 | $143,817226 claims |
| AstraZenecaFarxiga, Brilinta | $224 | $143,397165 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Synjardy Xr | $56 | $125,651159 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $61 | $77,131135 claims |
| AbbVieVraylar, Linzess | $1,238 | $59,25857 claims |
| MerckJanuvia | $23 | $45,74454 claims |
| Johnson & JohnsonXarelto | $157 | $30,56756 claims |
| AmgenProlia | $32 | $27,71316 claims |
| BayerKerendia | $283 | $24,12424 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $227 | $23,44413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Wilmer
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.